Laura Roca-Alonso, PhD
Interim Chief Executive Officer
Laura is the Interim CEO of Tangram Therapeutics. Prior to this appointment, Laura served as COO/CBO of Tangram from April 2020 to March 2026. During this time, she played a key role in transforming Tangram’s operating model and positioning, driving in-house platform and portfolio development, and pipeline progression into the clinic.
Laura has broad experience in genetic medicines and company building, from platform development through clinical stage. Prior to Tangram, she held senior roles at Gyroscope Therapeutics (a retinal gene therapy company acquired by Novartis) and Silence Therapeutics, a NASDAQ listed RNAi company. Laura earned her PhD from Imperial College London, an MRes in Biomedicine from University College London (UCL), and a BSc in Biotechnology from Universitat Autònoma de Barcelona (UAB).
